Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in advanced HER2+ NSCLC
NCT04311034Phase 2Completed
- Sponsor
- RemeGen
- Start
- Sep 2018
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in non-small cell lung cancer (NSCLC), sponsored by RemeGen. Primary endpoints: Objective Response Rate at 15 months, Disease Control Rate at 15 months and 3 more. Started Sep 2018; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04311034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311034.